On this page

Pimobendan Chewable Tablets

Pimobendan

Veterinary ANADA Approved 6,325 adverse event reports

Overview

Source: Animal Drugs @ FDA
Proprietary name
Pimobendan Chewable Tablets
Active ingredient
Pimobendan
Application type
ANADA
Sponsor
Cronus Pharma Specialities India Private Ltd.
Applications on record
1
First published
May 12, 2026

Adverse event reports

Source: openFDA VeDDRA
6,325
Reports mentioning this ingredient
March 4, 2003 – March 26, 2026
1,851
Classified serious
per reporter assessment
358
Lack of expected efficacy
resistance signal
225
Human operator exposure
needle-stick or splash
Not a risk measure. Veterinary adverse event reports are influenced by how many animals are treated, reporting practice and product age. Reports do not establish that the product caused the event, and a single report can cover an entire herd or flock. Attribution here is by active ingredient because the source dataset redacts brand names.

Attributed by active ingredient “PIMOBENDAN”. Green Book ingredient names and VeDDRA ingredient names do not always agree exactly, so attribution is approximate and labelled as such.

Reported reactions

Source: openFDA VeDDRA

Clinical signs coded in the VICH VeDDRA four-level hierarchy, most frequent first.

Reaction terms reported for this ingredient, by report count.
Reaction (VeDDRA term) Reports Relative frequency
Diarrhoea 636
Vomiting 636
Tablets, Abnormal 397
Death 325
Cough 313
Lethargy (see also Central nervous system depression in 'Neurological') 303
Anorexia 300
Death by euthanasia 257
Accidental exposure 212
Tachycardia 160
Lack of efficacy - NOS 143
Product Defect, General 140
Elevated blood urea nitrogen (BUN) 133
Seizure NOS 130
Lethargy (see also Central nervous system depression in Neurological) 127
Depression 124
Overdose 119
Decreased appetite 116
Ataxia 114
Elevated alanine aminotransferase (ALT) 112

Species affected

Source: openFDA VeDDRA
Dog 5,258 Cat 144 Human 39 Other Birds 2 Rabbit 2 Macaw 1 Chinchilla 1

Regulatory context

Abbreviated New Animal Drug Application (ANADA). A generic animal drug demonstrating bioequivalence, pharmaceutical equivalence and identical manufacturing criteria to the pioneer application. Veterinary generics have no formal therapeutic-equivalence coding system; they match the pioneer NADA specification instead.

Extra-label use in food-producing animals is governed by the Animal Medicinal Drug Use Clarification Act of 1994 (AMDUCA) and 21 CFR Part 530. It requires a valid veterinarian-client-patient relationship and is prohibited outright for certain drug classes. Withdrawal times are determined by FARAD, not by this index.

Sources for this page

Animal Drugs @ FDA FDA CVM Applications, sponsor, status, withdrawal
Animal & Veterinary Events FDA CVM VeDDRA adverse event aggregates by active ingredient